Dare Bioscience, Inc. (NASDAQ:DARE) Short Interest Down 32.4% in December

Dare Bioscience, Inc. (NASDAQ:DARE) was the recipient of a significant drop in short interest during the month of December. As of December 31st, there was short interest totaling 314,953 shares, a drop of 32.4% from the December 15th total of 466,123 shares. Based on an average trading volume of 202,947 shares, the short-interest ratio is currently 1.6 days. Currently, 2.3% of the shares of the company are sold short. Currently, 2.3% of the shares of the company are sold short. Based on an average trading volume of 202,947 shares, the short-interest ratio is currently 1.6 days.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Dare Bioscience in a research report on Tuesday, December 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of Dare Bioscience in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Dare Bioscience presently has an average rating of “Hold” and a consensus target price of $10.00.

Dare Bioscience Price Performance

NASDAQ DARE opened at $1.93 on Friday. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.06. The company has a fifty day simple moving average of $1.95 and a 200 day simple moving average of $2.11. The company has a market cap of $27.58 million, a P/E ratio of -1.03 and a beta of 0.78. Dare Bioscience has a 1 year low of $1.61 and a 1 year high of $9.19.

Dare Bioscience (NASDAQ:DARE) last announced its earnings results on Thursday, November 13th. The biotechnology company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.05. The business had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.01 million. On average, sell-side analysts predict that Dare Bioscience will post -0.49 EPS for the current year.

Institutional Trading of Dare Bioscience

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Raymond James Financial Inc. lifted its position in shares of Dare Bioscience by 810.6% during the third quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 13,650 shares in the last quarter. Virtu Financial LLC bought a new stake in Dare Bioscience in the third quarter valued at approximately $37,000. Finally, AMH Equity Ltd raised its stake in Dare Bioscience by 17.8% during the 2nd quarter. AMH Equity Ltd now owns 193,603 shares of the biotechnology company’s stock worth $463,000 after buying an additional 29,301 shares during the period. Institutional investors own 6.70% of the company’s stock.

About Dare Bioscience

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.